Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 022314

Expand all

EXFORGE HCT (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN)
5MG;12.5MG;160MG Marketing Status: Prescription

Active Ingredient: AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Proprietary Name: EXFORGE HCT
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 5MG;12.5MG;160MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022314
Product Number: 001
Approval Date: Apr 30, 2009
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXFORGE HCT (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN)
5MG;25MG;160MG Marketing Status: Prescription

Active Ingredient: AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Proprietary Name: EXFORGE HCT
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 5MG;25MG;160MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022314
Product Number: 002
Approval Date: Apr 30, 2009
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXFORGE HCT (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN)
10MG;12.5MG;160MG Marketing Status: Prescription

Active Ingredient: AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Proprietary Name: EXFORGE HCT
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG;12.5MG;160MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022314
Product Number: 003
Approval Date: Apr 30, 2009
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXFORGE HCT (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN)
10MG;25MG;160MG Marketing Status: Prescription

Active Ingredient: AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Proprietary Name: EXFORGE HCT
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG;25MG;160MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N022314
Product Number: 004
Approval Date: Apr 30, 2009
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

EXFORGE HCT (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN)
10MG;25MG;320MG Marketing Status: Prescription

Active Ingredient: AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
Proprietary Name: EXFORGE HCT
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 10MG;25MG;320MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N022314
Product Number: 005
Approval Date: Apr 30, 2009
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English